eligibility_summary
Adults (≥18) with LAPC/UPC or MPC, SD ≥3 months after ≥1 prior line (gem, 5‑FU/capecitabine, or nab‑paclitaxel), prior indicated targeted/immunotherapy, measurable disease (irRECIST), ECOG 0–1, adequate organ/cardiac function. Exclude: cetuximab allergy, recent investigational therapy or surgery/wounds, active infection or HBV/HCV/HIV/TB, live vaccine ≤30d, recent MI, autoimmune disease on immunosuppression, breastfeeding, incarcerated/detained, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06479239 (Phase I/II, single-arm). Intervention: EGFR FPBMC—an autologous cell-based immunotherapy made by arming a patient’s fresh peripheral blood mononuclear cells (primarily T cells) ex vivo with an anti-CD3 x anti-EGFR bispecific antibody. Drug type: bispecific antibody–armed cell product (not CAR-T). Mechanism: the bispecific antibody bridges CD3 on T cells to EGFR on tumor cells, activating and redirecting T-cell cytotoxicity against EGFR-expressing pancreatic cancer cells after reinfusion, repeated dosing aims to sustain T-cell activity and expansion. Targets: CD3/T-cell receptor complex on T cells, EGFR on tumor cells, pathways include T-cell activation and EGFR-expressing tumor cell killing.